Beginnetje van de lijst:
LSD – assisted psychotherapy
in persons suffering from anxiety
associated with advanced-stage life threatening diseases.
A phase-II, double-blind, placebo-controlled dose-response pilot study
- Principal Investigator: Peter Oehen, MD, with co-therapist Verena Widmer, RN
Location: Solothurn, Switzerland
This study is currently underway; all 12 subjects with treatment-resistant PTSD have undergone the experimental treatment. The final subject's last visit took place on January 8, 2010. The investigators are currently collecting data for the one-year, long-term follow-up phase of the study. The final analysis is scheduled for completion in January 2011, after the last measurements are collected from the final subject. We anticipate that the results will be submitted for publication in Spring 2011.
Our Swiss MDMA/PTSD pilot study has full approval from an Ethics Committee (Swiss IRB equivalent) and SwissMedic (FDA equivalent). The protocol has also been submitted to, and accepted by, the FDA under MAPS’ Investigational New Drug (IND) application for MDMA. The study is a part of MAPS’ clinical plan to develop MDMA into a prescription medicine approved by both the FDA and the European Medicines’ Agency (EMEA).
Swiss MDMA/PTSD pilot study protocol
The study will cost $260,000; $5,000 is still needed.
- LSD-gebruik in Vlaanderen : motieven en gebruikspatronen / door Van Bockxlaer Bram.
MISSING, ref url: